Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Bgne crawled time : 12:00 save search
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
Published: 2024-04-23 (Crawled : 12:00) - biospace.com/
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 4.09%
H: 0.0%
C: 0.0%
lung approval cancer cell treatment for
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
Published: 2024-03-06 (Crawled : 12:00) - biospace.com/
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 0.54%
H: 0.46%
C: -1.09%
pipeline preclinical meeting
BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
Published: 2024-02-27 (Crawled : 12:00) - biospace.com/
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 2.93%
H: 9.05%
C: 8.94%
tevimbra fda license application
Zymeworks Announces Participation in Upcoming March 2024 Investor Conferences
Published: 2024-02-27 (Crawled : 12:00) - biospace.com/
ZYME | $8.56 -1.72% -1.75% 340K
|
Health Technology
|
| O: 1.21%
H: 4.95%
C: 3.04%
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 2.93%
H: 9.05%
C: 8.94%
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
Published: 2024-02-26 (Crawled : 12:00) - biospace.com/
XNCR | $18.35 0.77% 0.76% 480K
|
Health Technology
|
| O: -0.29%
H: 7.38%
C: 6.02%
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 2.6%
H: 1.87%
C: 0.7%
business year financial results
Zymeworks Announces Participation in Upcoming Investor Conferences - Jan 31, 2024
Published: 2024-01-31 (Crawled : 12:00) - biospace.com/
ZYME | $8.56 -1.72% -1.75% 340K
|
Health Technology
|
| O: -0.09%
H: 3.57%
C: 0.56%
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: -1.44%
H: 0.26%
C: -2.99%
SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-08 (Crawled : 12:00) - globenewswire.com
SWTX | $43.96 2.5% 2.43% 870K
|
Health Technology
|
| O: -1.58%
H: 11.22%
C: 11.16%
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 0.36%
H: 3.65%
C: 3.35%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.5%
H: 3.18%
C: 3.12%
conference therapeutics
Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025
Published: 2024-01-04 (Crawled : 12:00) - globenewswire.com
ZYME | $8.56 -1.72% -1.75% 340K
|
Health Technology
|
| O: 1.03%
H: 1.67%
C: 0.46%
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 0.2%
H: 0.02%
C: -3.36%
AMGEN PRESENTS NEW TARLATAMAB DATA IN SMALL CELL LUNG CANCER
Published: 2023-10-20 (Crawled : 12:00) - prnewswire.com
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: -1.33%
H: 5.87%
C: 5.53%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 0.0%
H: 0.16%
C: -0.64%
lung cancer cell
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)
Published: 2023-09-19 (Crawled : 12:00) - biospace.com/
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 0.16%
H: 1.03%
C: -0.19%
tevimbra antibody global novartis
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®
Published: 2023-09-19 (Crawled : 12:00) - biospace.com/
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 0.16%
H: 1.03%
C: -0.19%
tevimbra europe positive global
Zymeworks Announces Participation in Upcoming Investor Conferences
Published: 2023-08-01 (Crawled : 12:00) - globenewswire.com
ZYME | $8.56 -1.72% -1.75% 340K
|
Health Technology
|
| O: 1.22%
H: 0.8%
C: -0.27%
MS | News 0 d | $93.76 1.81% 0.12% 6.4M
|
Finance
|
| O: -0.76%
H: 0.25%
C: -0.29%
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: -3.72%
H: 0.54%
C: -2.22%
Zymeworks To Host Second Quarter 2023 Results Conference Call
Published: 2023-07-19 (Crawled : 12:00) - globenewswire.com
ZYME | $8.56 -1.72% -1.75% 340K
|
Health Technology
|
| O: 0.38%
H: 2.15%
C: -0.25%
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 0.04%
H: 1.34%
C: -0.84%
conference results
Zymeworks Set to Join Russell 3000®, Russell 2000®, and Russell Microcap® Indexes
Published: 2023-06-26 (Crawled : 12:00) - globenewswire.com
ZYME | $8.56 -1.72% -1.75% 340K
|
Health Technology
|
| O: -0.12%
H: 0.93%
C: -2.47%
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 2.62%
H: 0.99%
C: -2.11%
3000 set
Zymeworks Announces Participation in Upcoming Investor Conferences
Published: 2023-06-01 (Crawled : 12:00) - globenewswire.com
ZYME | $8.56 -1.72% -1.75% 340K
|
Health Technology
|
| O: 0.12%
H: 4.73%
C: 3.03%
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: -0.0%
H: 2.87%
C: 1.16%
BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia
Published: 2023-05-30 (Crawled : 12:00) - biospace.com/
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 0.15%
H: 1.79%
C: -3.79%
brukinsa approved treatment canada leukemia
Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer
Published: 2023-05-18 (Crawled : 12:00) - globenewswire.com
ZYME | $8.56 -1.72% -1.75% 340K
|
Health Technology
|
| O: 0.54%
H: 4.11%
C: 3.79%
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: -1.16%
H: 0.78%
C: 0.18%
BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments
Published: 2023-05-04 (Crawled : 12:00) - biospace.com/
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: -2.93%
H: 2.3%
C: 1.31%
financial results
Jazz Pharmaceuticals to Showcase Rapidly Expanding Oncology Pipeline and Advances in Current Product Portfolio at ASCO 2023
Published: 2023-04-27 (Crawled : 12:00) - prnewswire.com
JAZZ | $109.685 0.79% 0.78% 380K
|
Health Technology
|
| O: 0.34%
H: 1.55%
C: 0.46%
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 1.03%
H: 2.97%
C: 2.78%
asco pipeline pharmaceuticals
Leap Therapeutics Announces First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients
Published: 2022-10-17 (Crawled : 12:00) - biospace.com/
LPTX | $3.24 0.94% 0.93% 89K
|
Health Technology
|
| O: -1.14%
H: 4.6%
C: 3.24%
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 4.91%
H: 6.28%
C: 2.04%
dkn-01 treatment therapeutics leap cancer study
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.